Johnson & Johnson Reports 2010 Second-Quarter Results:

Sales of $15.3 Billion Increased 0.6% Versus 2009 Second-Quarter; EPS was $1.23 Excluding Special Items, 2010 Second-Quarter EPS was $1.21, an increase of 5.2%*

News provided by

Johnson & Johnson

Jul 20, 2010, 07:45 ET

NEW BRUNSWICK, N.J., July 20 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

Net earnings and diluted earnings per share for the second quarter of 2010 were $3.4 billion and $1.23, respectively. Second-quarter 2010 net earnings included an after-tax gain of $67 million representing the net impact of litigation matters. Excluding this special item, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.21, representing increases of 5.4% and 5.2%, respectively, as compared to the same period in 2009.*

The Company updated its earnings guidance for full-year 2010 to $4.65 - $4.75 per share, which excludes the impact of special items. The Company's guidance now reflects the impact of the voluntary recalls announced earlier this year of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., as well as unfavorable changes in foreign currency exchange rates.

"Our second-quarter results include strong growth in a number of our recently launched products which contributed to solid earnings," said William C. Weldon, Chairman and Chief Executive Officer. "Remedial actions to address the product quality issues at McNeil Consumer Healthcare are ongoing and of high importance. At the same time, we continue to make significant investments in acquisitions, strategic partnerships and in advancing our pipeline, positioning us well for future growth."

Worldwide Consumer sales of $3.6 billion for the second quarter represented a decrease of 5.4% versus the prior year consisting of an operational decline of 6.5% and a positive impact from currency of 1.1%. Domestic sales decreased 14.3%; international sales increased 1.8%, which reflected an operational decline of 0.2% and a positive currency impact of 2.0%.

Positive contributors to operational results were NEUTROGENA®, international sales of Baby Care products and JOHNSON'S® adult skin products. These operational sales increases were more than offset by the impact of the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the economic situation in Venezuela.

Worldwide Pharmaceutical sales of $5.6 billion for the second quarter represented an increase of 1.0% versus the prior year with operational growth of 1.0% with no impact from currency. Domestic sales decreased 2.0%; international sales increased 5.0%, which reflected an operational increase of 4.9% and a positive currency impact of 0.1%.

Sales growth includes the strong performance of newly launched products including STELARA^™ (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI^™(golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® SUSTENNA^™ (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.

Several other products had strong operational growth including PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; international sales of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication; and INTELENCE®(etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV.

Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by continued generic competition.

During the quarter, the Company acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.

Additionally the Company signed an exclusive agreement with Diamyd Medical AB to develop and commercialize the GAD65 antigen-based diabetes therapy.

Worldwide Medical Devices and Diagnostics sales of $6.1 billion for the second quarter represented an increase of 4.1% versus the prior year consisting of an operational increase of 3.5% and a positive currency impact of 0.6%. Domestic sales increased 3.2%; international sales increased 5.0%, which reflected an operational increase of 3.9% and a positive currency impact of 1.1%.

Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.

During the quarter, the Company received clearance from the United States Food and Drug Administration to market narafilcon B, the first and only silicone hydrogel daily disposable contact lens in the United States, which will be marketed under the name 1-DAY ACUVUE® TruEye^™ Brand Contact Lenses.

In July, the Company entered into a definitive agreement to acquire Micrus Endovascular, a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke. Also in July, Ethicon Endo-Surgery completed the divestiture of its Breast Care business to Devicor Medical Products, Inc.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as the net impact of litigation gains, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure can be found in the Investor Relations section of the Company's website at www.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER						SIX MONTHS
			Percent Change						Percent Change
	2010	2009	Total		Operations	Currency	2010	2009	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 1,463	1,708	(14.3)	%	(14.3)	-	$ 3,023	3,434	(12.0)	%	(12.0)	-
International	2,184	2,146	1.8		(0.2)	2.0	4,390	4,131	6.3		0.6	5.7
	3,647	3,854	(5.4)		(6.5)	1.1	7,413	7,565	(2.0)		(5.1)	3.1

Pharmaceutical
U.S.	3,110	3,172	(2.0)		(2.0)	-	6,316	6,846	(7.7)		(7.7)	-
International	2,443	2,326	5.0		4.9	0.1	4,875	4,432	10.0		5.7	4.3
	5,553	5,498	1.0		1.0	0.0	11,191	11,278	(0.8)		(2.5)	1.7

Med Devices & Diagnostics
U.S.	2,865	2,776	3.2		3.2	-	5,751	5,428	6.0		6.0	-
International	3,265	3,111	5.0		3.9	1.1	6,606	5,994	10.2		5.6	4.6
	6,130	5,887	4.1		3.5	0.6	12,357	11,422	8.2		5.8	2.4

U.S.	7,438	7,656	(2.8)		(2.8)	-	15,090	15,708	(3.9)		(3.9)	-
International	7,892	7,583	4.1		3.0	1.1	15,871	14,557	9.0		4.2	4.8
Worldwide	$ 15,330	15,239	0.6	%	0.1	0.5	$ 30,961	30,265	2.3	%	0.0	2.3

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER						SIX MONTHS
			Percent Change						Percent Change
	2010	2009	Total		Operations	Currency	2010	2009	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 7,438	7,656	(2.8)	%	(2.8)	-	$ 15,090	15,708	(3.9)	%	(3.9)	-

Europe	3,832	3,972	(3.5)		1.3	(4.8)	7,934	7,643	3.8		2.9	0.9
Western Hemisphere excluding U.S.	1,375	1,215	13.2		2.6	10.6	2,655	2,277	16.6		3.1	13.5
Asia-Pacific, Africa	2,685	2,396	12.1		6.1	6.0	5,282	4,637	13.9		6.9	7.0
International	7,892	7,583	4.1		3.0	1.1	15,871	14,557	9.0		4.2	4.8

Worldwide	$ 15,330	15,239	0.6	%	0.1	0.5	$ 30,961	30,265	2.3	%	0.0	2.3

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER

	2010			2009			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 15,330		100.0	$ 15,239		100.0	0.6
Cost of products sold	4,630		30.2	4,450		29.2	4.0
Selling, marketing and administrative expenses	4,756		31.0	4,797		31.5	(0.9)
Research expense	1,648		10.8	1,638		10.7	0.6
Interest (income)expense, net	58		0.4	85		0.6
Other (income)expense, net	18		0.1	6		-
Earnings before provision for taxes on income	4,220		27.5	4,263		28.0	(1.0)
Provision for taxes on income	771		5.0	1,055		6.9	(26.9)
Net earnings	$ 3,449		22.5	$ 3,208		21.1	7.5

Net earnings per share (Diluted)	$ 1.23			$ 1.15			7.0

Average shares outstanding (Diluted)	2,796.0			2,782.0

Effective tax rate	18.3	%		24.7	%

Adjusted earnings before provision for taxes and net earnings
Earnings before provision for taxes on income	$ 4,377	(1)	28.6	$ 4,263		28.0	2.7
Net earnings	$ 3,382	(1)	22.1	$ 3,208		21.1	5.4
Net earnings per share (Diluted)	$ 1.21	(1)		$ 1.15			5.2
Effective tax rate	22.7	%		24.7	%

(1) The difference between as reported and as adjusted earnings is the exclusion of second quarter net litigation. The impact of second quarter net litigation is $157 million expense on earnings before provision for taxes on income, $67 million income on net earnings and $0.02 per share on net earnings per share (diluted).

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS

	2010			2009			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 30,961		100.0	$ 30,265		100.0	2.3
Cost of products sold	9,158		29.6	8,701		28.7	5.3
Selling, marketing and administrative expenses	9,535		30.8	9,405		31.1	1.4
Research expense	3,205		10.4	3,156		10.4	1.6
Interest (income)expense, net	139		0.4	166		0.6
Other (income)expense, net	(1,576)		(5.1)	(69)		(0.2)
Earnings before provision for taxes on income	10,500		33.9	8,906		29.4	17.9
Provision for taxes on income	2,525		8.1	2,191		7.2	15.2
Net earnings	$ 7,975		25.8	$ 6,715		22.2	18.8

Net earnings per share (Diluted)	$ 2.85			$ 2.41			18.3

Average shares outstanding (Diluted)	2,796.1			2,785.5

Effective tax rate	24.0	%		24.6	%

Adjusted earnings before provision for taxes and net earnings
Earnings before provision for taxes on income	$ 9,160	(1)	29.6	$ 8,906		29.4	2.9
Net earnings	$ 6,998	(1)	22.6	$ 6,715		22.2	4.2
Net earnings per share (Diluted)	$ 2.50	(1)		$ 2.41			3.7
Effective tax rate	23.6	%		24.6	%

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of income from net litigation of $1,340 million, $977 million and $0.35 per share, respectively.

	REPORTED SALES vs. PRIOR PERIOD ($MM)
	SECOND QUARTER					SIX MONTHS
			% Change					% Change
	2010	2009	Reported	Operational (1)	Currency	2010	2009	Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)
SKIN CARE
US	422	411	2.7%	2.7%	-	874	834	4.8%	4.8%	-
Intl	421	422	-0.2%	-0.5%	0.3%	889	841	5.7%	0.9%	4.8%
WW	843	833	1.2%	1.1%	0.1%	1,763	1,675	5.3%	2.9%	2.4%
BABY CARE
US	99	104	-4.8%	-4.8%	-	202	206	-1.9%	-1.9%	-
Intl	438	404	8.4%	4.9%	3.5%	864	791	9.2%	3.1%	6.1%
WW	537	508	5.7%	2.9%	2.8%	1,066	997	6.9%	2.1%	4.8%
ORAL CARE
US	148	174	-14.9%	-14.9%	-	322	362	-11.0%	-11.0%	-
Intl	224	212	5.7%	1.8%	3.9%	431	389	10.8%	3.3%	7.5%
WW	372	386	-3.6%	-5.8%	2.2%	753	751	0.3%	-3.6%	3.9%
OTC/NUTRITIONALS
US	492	679	-27.5%	-27.5%	-	1,034	1,405	-26.4%	-26.4%	-
Intl	649	631	2.9%	1.9%	1.0%	1,314	1,253	4.9%	-0.5%	5.4%
WW	1,141	1,310	-12.9%	-13.4%	0.5%	2,348	2,658	-11.7%	-14.3%	2.6%
WOMEN'S HEALTH
US	137	152	-9.9%	-9.9%	-	283	301	-6.0%	-6.0%	-
Intl	329	329	0.0%	-2.1%	2.1%	652	603	8.1%	2.4%	5.7%
WW	466	481	-3.1%	-4.5%	1.4%	935	904	3.4%	-0.4%	3.8%
WOUND CARE / OTHER
US	165	188	-12.2%	-12.2%	-	308	326	-5.5%	-5.5%	-
Intl	123	148	-16.9%	-20.3%	3.4%	240	254	-5.5%	-11.4%	5.9%
WW	288	336	-14.3%	-15.8%	1.5%	548	580	-5.5%	-8.1%	2.6%
TOTAL CONSUMER
US	1,463	1,708	-14.3%	-14.3%	-	3,023	3,434	-12.0%	-12.0%	-
Intl	2,184	2,146	1.8%	-0.2%	2.0%	4,390	4,131	6.3%	0.6%	5.7%
WW	3,647	3,854	-5.4%	-6.5%	1.1%	7,413	7,565	-2.0%	-5.1%	3.1%


* See footnotes below


PHARMACEUTICAL SEGMENT (2) (6)
ACIPHEX/PARIET
US	121	128	-5.5%	-5.5%	-	240	266	-9.8%	-9.8%	-
Intl	133	132	0.8%	2.1%	-1.3%	274	257	6.6%	2.7%	3.9%
WW	254	260	-2.3%	-1.6%	-0.7%	514	523	-1.7%	-3.6%	1.9%
CONCERTA
US	223	233	-4.3%	-4.3%	-	454	502	-9.6%	-9.6%	-
Intl	100	84	19.0%	16.3%	2.7%	198	159	24.5%	16.7%	7.8%
WW	323	317	1.9%	1.2%	0.7%	652	661	-1.4%	-3.3%	1.9%
DURAGESIC/FENTANYL TRANSDERMAL
US	37	50	-26.0%	-26.0%	-	75	125	-40.0%	-40.0%	-
Intl	147	168	-12.5%	-12.6%	0.1%	293	324	-9.6%	-13.1%	3.5%
WW	184	218	-15.6%	-15.7%	0.1%	368	449	-18.0%	-20.5%	2.5%
LEVAQUIN/FLOXIN
US	289	343	-15.7%	-15.7%	-	652	751	-13.2%	-13.2%	-
Intl	11	19	-42.1%	-44.8%	2.7%	19	36	-47.2%	-50.2%	3.0%
WW	300	362	-17.1%	-17.2%	0.1%	671	787	-14.7%	-14.8%	0.1%
PREZISTA
US	99	65	52.3%	52.3%	-	188	137	37.2%	37.2%	-
Intl	105	75	40.0%	42.1%	-2.1%	203	125	62.4%	57.3%	5.1%
WW	204	140	45.7%	46.8%	-1.1%	391	262	49.2%	46.8%	2.4%
PROCRIT/EPREX
US	306	330	-7.3%	-7.3%	-	596	651	-8.4%	-8.4%	-
Intl	220	247	-10.9%	-9.3%	-1.6%	453	476	-4.8%	-7.8%	3.0%
WW	526	577	-8.8%	-8.1%	-0.7%	1,049	1,127	-6.9%	-8.2%	1.3%
REMICADE
US	783	771	1.6%	1.6%	-	1,563	1,508	3.6%	3.6%	-
US Exports (3)	341	327	4.3%	4.3%	-	741	613	20.9%	20.9%	-
Intl	6	4	50.0%	50.0%	-	12	9	33.3%	33.2%	0.1%
WW	1,130	1,102	2.5%	2.5%	-	2,316	2,130	8.7%	8.7%	-
RISPERDAL/RISPERIDONE
US	(17)	70	-124.3%	-124.3%	-	(12)	188	-106.4%	-106.4%	-
Intl	134	169	-20.7%	-22.1%	1.4%	267	326	-18.1%	-21.2%	3.1%
WW	117	239	-51.0%	-52.0%	1.0%	255	514	-50.4%	-52.4%	2.0%
RISPERDAL CONSTA
US	115	131	-12.2%	-12.2%	-	232	257	-9.7%	-9.7%	-
Intl	240	217	10.6%	12.8%	-2.2%	502	416	20.7%	16.9%	3.8%
WW	355	348	2.0%	3.4%	-1.4%	734	673	9.1%	6.8%	2.3%
TOPAMAX
US	59	75	-21.3%	-21.3%	-	116	570	-79.6%	-79.6%	-
Intl	83	107	-22.4%	-21.4%	-1.0%	174	214	-18.7%	-21.6%	2.9%
WW	142	182	-22.0%	-21.4%	-0.6%	290	784	-63.0%	-63.8%	0.8%
VELCADE
US	-	-	-	-	-	-	-	0.0%	0.0%	-
Intl	286	229	24.9%	25.1%	-0.2%	547	421	29.9%	25.8%	4.1%
WW	286	229	24.9%	25.1%	-0.2%	547	421	29.9%	25.8%	4.1%
OTHER
US	754	649	16.2%	16.2%	-	1,471	1,278	15.1%	15.1%	-
Intl	978	875	11.8%	10.3%	1.5%	1,933	1,669	15.8%	10.5%	5.3%
WW	1,732	1,524	13.6%	12.8%	0.8%	3,404	2,947	15.5%	12.5%	3.0%
TOTAL PHARMACEUTICAL
US	3,110	3,172	-2.0%	-2.0%	-	6,316	6,846	-7.7%	-7.7%	-
Intl	2,443	2,326	5.0%	4.9%	0.1%	4,875	4,432	10.0%	5.7%	4.3%
WW	5,553	5,498	1.0%	1.0%	0.0%	11,191	11,278	-0.8%	-2.5%	1.7%
MAJOR NEW PHARM PRODUCTS (4)
INVEGA
US	68	67	1.5%	1.5%	-	137	133	3.0%	3.0%	-
Intl	34	32	6.3%	8.3%	-2.0%	73	57	28.1%	23.8%	4.3%
WW	102	99	3.0%	3.6%	-0.6%	210	190	10.5%	9.2%	1.3%

* See footnotes below
MEDICAL DEVICES AND DIAGNOSTICS (2)
CORDIS (5)
US	265	252	5.2%	5.2%	-	516	498	3.6%	3.6%	-
Intl	390	422	-7.6%	-8.6%	1.0%	811	844	-3.9%	-7.4%	3.5%
WW	655	674	-2.8%	-3.4%	0.6%	1,327	1,342	-1.1%	-3.3%	2.2%
DEPUY
US	776	762	1.8%	1.8%	-	1,590	1,528	4.1%	4.1%	-
Intl	599	561	6.8%	6.0%	0.8%	1,239	1,087	14.0%	8.5%	5.5%
WW	1,375	1,323	3.9%	3.5%	0.4%	2,829	2,615	8.2%	5.9%	2.3%
DIABETES CARE
US	313	306	2.3%	2.3%	-	603	576	4.7%	4.7%	-
Intl	303	304	-0.3%	1.1%	-1.4%	610	575	6.1%	3.2%	2.9%
WW	616	610	1.0%	1.7%	-0.7%	1,213	1,151	5.4%	4.0%	1.4%
ETHICON
US	509	452	12.6%	12.6%	-	1,019	857	18.9%	18.9%	-
Intl	623	589	5.8%	5.0%	0.8%	1,260	1,137	10.8%	6.1%	4.7%
WW	1,132	1,041	8.7%	8.2%	0.5%	2,279	1,994	14.3%	11.6%	2.7%
ETHICON ENDO-SURGERY
US	507	489	3.7%	3.7%	-	990	943	5.0%	5.0%	-
Intl	689	626	10.1%	8.8%	1.3%	1,374	1,187	15.8%	10.7%	5.1%
WW	1,196	1,115	7.3%	6.6%	0.7%	2,364	2,130	11.0%	8.2%	2.8%
ORTHO-CLINICAL DIAGNOSTICS
US	264	284	-7.0%	-7.0%	-	552	561	-1.6%	-1.6%	-
Intl	230	210	9.5%	8.4%	1.1%	467	400	16.8%	12.2%	4.6%
WW	494	494	0.0%	-0.5%	0.5%	1,019	961	6.0%	4.1%	1.9%
VISION CARE
US	232	231	0.4%	0.4%	-	481	465	3.4%	3.4%	-
Intl	430	399	7.8%	3.9%	3.9%	845	764	10.6%	5.4%	5.2%
WW	662	630	5.1%	2.6%	2.5%	1,326	1,229	7.9%	4.6%	3.3%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US	2,865	2,776	3.2%	3.2%	-	5,751	5,428	6.0%	6.0%	-
Intl	3,265	3,111	5.0%	3.9%	1.1%	6,606	5,994	10.2%	5.6%	4.6%
WW	6,130	5,887	4.1%	3.5%	0.6%	12,357	11,422	8.2%	5.8%	2.4%

(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Reported in U.S. sales
(4) Included in Other
(5) Includes sales of Drug-Eluting Stents for Q2 2010 of $59, $108 and $167MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and $234MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2010 of $119, $238 and $357MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2009 of $136, $349 and $485MM Domestic, International and Worldwide respectively
(6) Conforms to current presentation